Company Overview and News

4
M&T Bank (MTB) Q3 Earnings Beat Estimates, Expenses Decline

34m zacks
M&T Bank Corporation (MTB - Free Report) reported net operating earnings of $3.56 per share in third-quarter 2018, surpassing the Zacks Consensus Estimate of $3.35. Also, the bottom line improved 59% year over year.
WFC WFCNP CMA

9
U.S. Bancorp (USB) Beats on Q3 Earnings, Expenses Flare Up

34m zacks
Riding on higher revenues and lower provisions, U.S. Bancorp’s (USB - Free Report) third-quarter 2018 earnings per share of $1.06 outpaced the Zacks Consensus Estimate of $1.04. Also, results came ahead of the prior-year quarter earnings of 88 cents. Shares of U.S. Bancorp climbed more than 1% in pre-market trading, highlighting investors’ optimism on higher revenues along with loan growth and lower provisions.
WFC WFCNP C USB

19
Prudential Financial no longer needs federal oversight, regulators say

1h thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
WFCNP MS WFC PRU GEC GE PFK PRH GNE PJH

4
LegacyTexas Financial Group (LTXB) CEO, Kevin Hanigan on Q3 2018 Results - Earnings Call Transcript

1h seekingalpha
Good morning and welcome to the LegacyTexas Q3 2018 Earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today’s presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. To withdraw your question, please press star then two.
WFC WFCNP MTSI LTXB

7
Why Berkshire Hathaway May Be Undervalued by Almost 20%

2h 247wallst
Very few analysts follow Berkshire Hathaway Inc. (NYSE: BRK-A). After all, it has so many moving parts and nearly 40% of its over $500 billion market capitalization can be attributed at the current time to its public equity holdings. What many investors have a hard time deciding is the value of its multiple subsidiaries under its conglomerate umbrella, and they have an even harder time projecting the potential use of its massive cash balances that can fund expansion and acquisitions.
WFC WFCNP BRK.A

2
WFC / Wells Fargo & Co. PRELIMINARY PRICING SUPPLEMENT NO. 156 (Prospectus)

2h sec.gov
Filed Pursuant to Rule 424(b)(2) Registration No. 333-221324
WFC

2
WFC / Wells Fargo & Co. DEFINITIVE PRICING SUPPLEMENT NO. 154 (Prospectus)

2h sec.gov
Filed Pursuant to Rule 424(b)(2) File No. 333-221324
WFC

2
WFC / Wells Fargo & Co. DEFINITIVE PRICING SUPPLEMENT NO. 150 (Prospectus)

2h sec.gov
Filed Pursuant to Rule 424(b)(2) Registration No. 333-221324
WFC

4
Bank execs tell a good economic story and investors are finally starting to believe them

3h cnbc
By any measure, including their own third quarter financial reports, big U.S. banks are signaling the economy is on solid ground. And shares of these big banks jumped on Tuesday, suggesting investors are starting to believe them.
WFC WFCNP MS

12
Top Research Reports for Pfizer, Caterpillar & Charter Communications

3h zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Pfizer (PFE), Caterpillar (CAT) and Charter Communications (CHTR). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
WFC WFCNP LMT ALGN UPS CAT ZTS HWC CHTR PFE

50
3 Reasons I’m Cautious Against Twilio Stock

2018-10-16 investorplace
Inarguably, Twilio (NYSE:TWLO) is one of the top technology surprises this year. Since the January opener, Twilio stock has skyrocketed over three-fold. For late-to-the-game investors, the temptation is to jump on this momentum train. However, both broader market weaknesses and a questionable acquisition suggests caution is in order.
WFC WFCNP BAC TWLO SEND

14
Big US banks end third quarter on high note

2018-10-16 channelnewsasia
Wall Street's top investment banks enjoyed a strong third quarter as strength in stock trading and equity underwriting added to the benefits from a strong U.S. economy and tax reforms.
GLSSP MS JBK TFG CGBBW WFCNP GS WFC C GSC GSJ GJS

4
Wells Fargo to shift European investment banking business to Paris as Brexit looms

2018-10-16 reuters
(Reuters) - Wells Fargo & Co (WFC.N) said on Tuesday it had applied for an investment firm license in France as part of a Brexit strategy to shift some of its servicing of European mainland customers out of London.
WFC WFCNP

14
GRAPHIC-Big U.S. banks end third quarter on high note

2018-10-16 reuters
(Reuters) - Wall Street’s top investment banks enjoyed a strong third quarter as strength in stock trading and equity underwriting added to the benefits from a strong U.S. economy and tax reforms.
GLSSP MS JBK TFG CGBBW WFCNP GS WFC C GSC GSJ GJS

4
Morgan Stanley's (MS) CEO James Gorman on Q3 2018 Results - Earnings Call Transcript

2018-10-16 seekingalpha
Good morning. This is Sharon Yeshaya, Head of Investor Relations. During today’s presentation, we will refer to our earnings release and financial supplement, copies of which are available at morganstanley.com. Today’s presentation may include forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially. Please refer to our notices regarding forward-looking statements and non-GAAP measures that appear in the earnings release.
WFC WFCNP DB MS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to WFC / Wells Fargo & Co. on message board site Silicon Investor.

WELLS FARGO WELLS FARGO WELLS FARGO Banks--- Betting on the recovery Banks--- Betting on the recovery Banks--- Betting on the recovery
Predatory Banking and the Housing Crisis Predatory Banking and the Housing Crisis Predatory Banking and the Housing Crisis T u0026 W FINANCIAL (TWFC) T u0026 W FINANCIAL (TWFC) T u0026 W FINANCIAL (TWFC)
CUSIP: 949746101